The American Society for Radiation Oncology (ASTRO) has issued a new guideline, The Role of Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based Guideline, that details the use of adjuvant radiation therapy in the treatment of endometrial cancer. The guideline's executive summary is published in the May-June 2014 issue of Practical Radiation Oncology (PRO), the official clinical practice journal of ASTRO. The full-length guideline is available as an open-access article online.
The American Society for Radiation Oncology (ASTRO) has
issued a new guideline, “The Role of Postoperative Radiation Therapy for Endometrial Cancer: An
ASTRO Evidence-Based Guideline,” that details the use of adjuvant radiation therapy in the
treatment of endometrial cancer. The guideline’s executive summary is published in the May-June
2014 issue of Practical Radiation Oncology (PRO), the official clinical practice journal of ASTRO.
The
full-length guideline is available as an open-access article online at www.practicalradonc.org.
ASTRO’s Guidelines Panel of 17 leading gynecologic specialists compiled and reviewed
extensive data from 330 studies from MEDLINE, EMBASE and the Specialized Register of the
Cochrane Gynaecological Cancer Review Group published from 1980 to 2011. The data population
selected for the guideline was defined as women of all races, age 18 or older, with stage I-IV
endometrial cancer of any histologic type or grade. The studies included patients who underwent a
hysterectomy followed by no adjuvant therapy, or pelvic and/or vaginal brachytherapy with or
without systemic chemotherapy. The panel identified five key questions about the role of adjuvant
radiation therapy and developed a series of recommendations to address each question.
Source: ASTRO
Read the press release here:
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More